The global food allergy diagnostics & therapeutics market size was valued at USD 2.69 billion in 2018 and is expected to grow at a lucrative CAGR of 7.4% over the forecast period. The rising prevalence of food allergy is anticipated to drive the market. Symptoms associated with the allergic response could range from itchiness, swelling of the tongue, or hives to low blood pressure, diarrhea, or vomiting.
According to the World Allergy Organization, the prevalence of food allergies is increasing globally. Some of the most common allergens are eggs, milk, wheat, fish, and tree nuts. Moreover, fish allergies are more prevalent in Asia than in western countries. In addition, rising awareness about food allergy and high unmet medical needs coupled with the introduction of novel products in the market are some of the other factors expected to contribute to the growth in the near future.
According to the American Academy of Pediatrics, 5.6 million children in the U.S. have food allergies, out of which around 40% have more than one allergy. It affects around 6% to 8% of children below 3 years of age and around 3% of the adult population. Increasing incidence of allergic conditions among both pediatric and adult populations drives the demand for cost-effective and advanced therapeutics.
In addition, technological advancements and an increase in the number of R&D initiatives being undertaken for the development of drugs with higher efficacy are some of the drivers of this market. With the introduction of epinephrine auto-injector, treatment for peanut allergy or allergy to a bee sting can be easily provided. However, the cost of EpiPen is USD 630, which makes it unaffordable for people in low-income countries.
Symptoms of food allergy vary from person to person and might not result in the same symptoms in different individuals. Food allergic reactions affect the respiratory tract, skin, cardiovascular system, and gastrointestinal tract. In order to gain knowledge about the severity of the allergies, proper counseling about the life-threatening risk factors of anaphylaxis should be undertaken.
The market is segmented into diagnostics and therapeutics. The therapeutics segment dominated the market in 2018 owing to growing awareness about various treatment modalities for the management of food allergies. This segment is further classified into antihistamines and epinephrine auto-injectors. Antihistamines segment held a significant share in 2018 owing to their wide usage as they act by directly blocking the release of histamine, specifically by binding to the H1 receptors present on glandular cells, smooth muscles, and nerve endings.
Diagnostic products include instruments, consumables, and services. Consumables are expected to exhibit lucrative growth over the forecast period, owing to the availability of various advanced and rapid test kits. For instance, IgG Food Intolerance Screening Test Kit used for the detection of food-specific IgG.
There are two diagnostic test types-in Vivo and in vitro. Rising demand for blood tests has led to the high growth of in vitro testing. Skin prick tests are also used widely to detect food allergies, thereby driving the adoption of in vivo testing in the market.
On the basis of allergen sources, peanut allergen dominated the food allergy diagnostics & therapeutics market in 2018 due to an increase in the prevalence of allergies caused due to peanuts. According to a study published by the American College of Allergy, Asthma, and Immunology (ACAAI) in 2017, peanut allergies in children increased by 21% since 2010. The data further stated that approximately 2.5% of children in the U.S. are allergic to peanuts.
In adults, food allergies occur due to common allergens including shellfish, peanuts, tree nuts, and fish; whereas children are commonly allergic to peanuts, tree nuts, eggs, milk, wheat, or soy. Around 90% of allergies are caused due to milk, soy, wheat, eggs, tree nuts, fish, shellfish, and peanuts.
On the basis of end-use, hospitals & clinics accounted for the largest market share in 2018, owing to an increase in the number of people seeking treatment for allergies. An increasing number of allergic cases requiring hospitalization is also a factor driving the segment. In addition, the growing risk for severe allergic reactions has increased instances of early therapeutic interventions in hospitals and clinics.
Diagnostic laboratories segment is expected to exhibit significant growth over the forecast period due to the extensive application of allergy diagnostic kits in disease diagnosis. Allergists commonly recommend a blood or skin test for food allergy diagnosis in order to assess the presence of food-specific immunoglobulin E antibodies in the body. Moreover, the rising number of diagnostic centers also contributes to the growth of diagnostic laboratories segment.
Europe dominated the market in 2018 due to an increase in the incidence of food allergies. Around 17 million people in Europe reported food allergies. Fourteen allergens were found to be the most common causes of food allergies and intolerance in this region. Increasing awareness about various available treatments for food allergies also drives the market in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to an increase in the number of food allergy cases, especially peanut allergy. This is mainly due to factors such as modernization and change in lifestyle. In addition, the growing population in the region is also driving the regional market.
Some of the major players in the market are Allergy Therapeutics; Cambridge Allergy Ltd; Astellas Pharma, Inc.; Immunomic Therapeutics, Inc.; Prota Therapeutics Pty Ltd; Aimmune Therapeutics; Meridian Medical Technologies; ALK-Abelló Ltd; Medeca Pharma AB; bioMérieux SA; Omega Diagnostics Group PLC; HYCOR Biomedical; and HOB Biotech Group Corp., Ltd.
They are increasingly adopting various strategies, such as new product development, mergers & acquisitions, and regional expansion. For instance, in 2017, Stallergenes Greer invested in Adeo, a research-driven food company, to develop novel treatments for food allergy.
Base year for estimation
Actual estimates/Historic data
2015 - 2017
2019 - 2026
Revenue in USD Million & CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, & MEA
U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, Japan, India, China, South Korea, Singapore
Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, & country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the food allergy diagnostics & therapeutics market report on the basis of product type, allergen source, end-use, and region:
Product Type Outlook (Revenue, USD Million, 2015 - 2026)
Skin Prick Test
Therapeutic Treatment Type
Allergen Source Outlook (Revenue, USD Million, 2015 - 2026)
End-use Outlook (Revenue, USD Million, 2015 - 2026)
Academic Research Institutes
Hospitals & Clinics
Regional Outlook (Revenue, USD Million, 2015 - 2026)
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.